DAFNA Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

DAFNA Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-278	Closed	-$595K	–	76
2018 Q2	$595K	Buy	+278	New	+$402K	0.28%	59
2016 Q2	–	Sell	-75	Closed	-$66K	–	98
2016 Q1	$66K	Buy	75 +8	+12%	+$7.84K	0.06%	88
2015 Q4	$91K	Buy	67 +34	+103%	+$54.3K	0.08%	73
2015 Q3	$44K	Buy	+33	New	+$54.3K	0.04%	87
2015 Q1	–	Sell	-878	Closed	-$917K	–	73
2014 Q4	$917K	Buy	878 +228	+35%	+$248K	0.73%	38
2014 Q3	$1.01M	Sell	650 -495	-43%	-$677K	1.01%	25
2014 Q2	$2.01M	Buy	1,145 +22	+2%	+$33.8K	1.9%	13
2014 Q1	$2.32M	Buy	+1,123	New	+$2.63M	1.99%	14

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DAFNA Capital Management's GLMD Position: Q3 2018 in Review

DAFNA Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q3 2018, closing a stake of 278 shares — an estimated $595K sold.

DAFNA Capital Management first reported a position in GLMD in Q1 2014 and held it in 8 quarters. The position peaked at $2.32M in Q1 2014. 38 funds tracked by Wall St. Rank hold GLMD as of Q3 2018.

DAFNA Capital Management reported no remaining Galmed Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
DAFNA Capital Management sold 278 Galmed Pharmaceuticals shares in Q3 2018, an estimated $595K.
DAFNA Capital Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 8 quarters.
DAFNA Capital Management's Galmed Pharmaceuticals position peaked at $2.32M in Q1 2014.
38 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2018.

Based on DAFNA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.